Healthcare >> CEO Interviews >> November 2, 2003
PAUL D. GOODSON has served as Vice President, Investor Relations of
Invitrogen Corporation since January 2001. He came to Invitrogen from
the Financial Relations Board, the world's largest investor relations
agency, where he was a Senior Account Group Manager and a Director of
its parent company, BSMG. Previously, he was Vice President of Investor
Relations at ECA, Inc., a developer of advanced engine technologies and
energy systems, and was later named President of that company. From 1983
to 1995, he held various positions in investor relations, marketing,
research and environmental affairs at Pacific Enterprises, a large
utility holding company, including the position of President of CERAC,
Inc. In prior positions at Tosco, Energy Resources Company and TRW, he
served as a lobbyist, senior scientist and process engineer. In 1980,
Mr. Goodson co-founded Phytogen, a plant genetics firm in Pasadena,
California, with one of his former Caltech professors. In 1983, he co-
founded International Biotechnology Company, which worked to develop a
single-dose hepatitis-B vaccine. He has served on the Boards of
Directors of ECA and Quantum Group, Inc., a San Diego-based developer of
carbon monoxide detection systems and other advanced chemical
technologies. He holds a secret-level clearance from the US Department
of Defense and a lifetime limited-service college teaching credential
for chemistry and engineering from the State of California. He is an
Adjunct Professor of Finance at the University of Phoenix and has taught
Chemistry at El Camino Junior College in Gardena, California. Mr.
Goodson holds BS and MS degrees in Chemical Engineering from Caltech
(with honors) and the University of Wisconsin, respectively, and an MBA
degree from UCLA. Profile
operations?
Mr. Goodson: This is literally a California garage story. It was founded
in 1987 by Lyle Turner and two
